{
    "clinical_study": {
        "@rank": "30074", 
        "arm_group": [
            {
                "arm_group_label": "3 x 10^6 cells", 
                "arm_group_type": "Experimental", 
                "description": "3 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8"
            }, 
            {
                "arm_group_label": "10 x 10^6 cells", 
                "arm_group_type": "Experimental", 
                "description": "10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8"
            }, 
            {
                "arm_group_label": "30 x 10^6 cells", 
                "arm_group_type": "Experimental", 
                "description": "30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8"
            }, 
            {
                "arm_group_label": "100 x 10^6 cells", 
                "arm_group_type": "Experimental", 
                "description": "100 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical study is being conducted to assess the safety and determine the maximum\n      tolerated dose (MTD) of PDA-002 [human placenta-derived cells] administered into the lower\n      leg muscles of subjects with peripheral arterial disease and diabetic foot ulcers.  It will\n      look to see if PDA-002 helps reduce some of the symptoms of PAD and/or improves ulcer\n      healing.  This study will also help to find the best dose of PDA-002 to use in future\n      studies."
        }, 
        "brief_title": "Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral Arterial Disease", 
            "Diabetic Foot"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases", 
                "Diabetic Foot"
            ]
        }, 
        "detailed_description": {
            "textblock": "The goal of this study is to determine a safe dose of PDA-002 [human placenta-derived cells]\n      for further study. This is a dose-escalation study where each of four dose levels will\n      enroll three to six subjects.  Doses will be range from 3 million up to 100 million cells.\n      If one dose is considered safe after all treated subjects have been evaluated and reviewed,\n      then the next group of subjects will be enrolled to receive the next higher dose.  This will\n      continue until either the highest dose is reached, until at least 2 subjects at a dose level\n      have \u2265 Grade 2 allergic reaction that is suspected to be related to PDA-002 or 2 or more\n      subjects at a dose level experience an unexpected, treatment-related serious adverse event\n      or dose limiting toxicity within 14 days following the initial dose of PDA-002.  This is an\n      open-label study where  all subjects will be taking the study drug and all study personnel\n      will know the dose each subject receives."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must satisfy the following criteria to be enrolled in the study:\n\n               1. Males and females, 18 to 80 years of age at the time of signing the informed\n                  consent document.\n\n               2. Understand and voluntarily sign an informed consent document prior to any study\n                  related assessments/procedures are conducted.\n\n               3. Able to adhere to the study visit schedule and other protocol requirements.\n\n               4. Diabetes mellitus type 2\n\n               5. Ischemic or neuro-ischemic diabetic foot ulcer with severity of  Grade 1 (full\n                  thickness only) or Grade 2 on the Wagner Grading Scale (Appendix A) of greater\n                  than one month duration which has not adequately responded to conventional ulcer\n                  therapy.\n\n               6. Peripheral arterial disease with ankle-brachial index > 0.6 and \u2264 0.9 or\n                  toe-brachial index > 0.35 and \u2264 0.7.\n\n               7. No planned revascularization or amputation over the next 3 months after\n                  Screening visit, in the opinion of the Investigator.\n\n               8. Not a candidate for peripheral artery percutaneous or surgical\n                  revascularization.\n\n               9. Screening should not begin until at least 2 weeks after a failed reperfusion\n                  intervention and at least 2 months after a successful mechanical intervention.\n\n              10. Subject can have stable angina, (Canadian Cardiovascular Society (CCS) Class\n                  I-II angina (Appendix H).\n\n              11. Subjects should be receiving appropriate medical therapy for hypertension and\n                  diabetes.\n\n              12. Subject must be a non-tobacco user defined as someone who has not used\n                  tobacco/nicotine patch for \u2265 3 months and must agree to remain tobacco/nicotine\n                  free for the duration of the study.\n\n              13. A female of childbearing potential [FCBP] must have a negative serum pregnancy\n                  test at Screening and a negative urine pregnancy test prior to treatment with\n                  study therapy.  In addition, sexually active FCBP must agree to use 2 of the\n                  following adequate forms of contraception methods simultaneously such as: oral,\n                  injectable, or implantable hormonal contraception; tubal ligation; intrauterine\n                  device [IUD]; barrier contraceptive with spermicide or vasectomized partner for\n                  the duration of the study and the follow-up period.\n\n              14. Males (including those who have had a vasectomy) must agree to use barrier\n                  contraception (latex condoms) when engaging in reproductive sexual activity with\n                  FCBP for the duration of the study and the follow-up period.\n\n                  Exclusion Criteria:\n\n          -  The presence of any of the following will exclude a subject from enrollment:\n\n               1. Any significant medical condition, laboratory abnormality, or psychiatric\n                  illness that would prevent the subject from participating in the study.\n\n               2. Any condition including the presence of laboratory abnormalities, which places\n                  the subject at unacceptable risk if he or she were to participate in the study.\n\n               3. Any condition that confounds the ability to interpret data from the study.\n\n               4. Subjects whom, in the judgment of the Investigator, are at elevated risk for the\n                  development of a malignancy. This judgment may be based on family history,\n                  history of industrial exposures, smoking history or other cancer risk factors.\n\n               5. Known to be positive for human immunodeficiency virus.\n\n               6. Pregnant or lactating females.\n\n               7. Subjects with a body mass index > 35 at Screening.\n\n               8. Aspartate transaminase (AST)  or Alanine transaminase (ALT) > 2.5 x the upper\n                  limit of normal (ULN) at Screening.\n\n               9. Estimated Glomerular Filtration Rate (eGFR) < 45 mL/min/1.73 m2 at Screening\n                  calculated using the Modification of Diet in Renal Disease Study equation\n                  (Levey, 2006) or history of eGFR decline > 15 mL/min/1.73 m2 in the past year.\n\n              10. Alkaline phosphatase > 2.5 x the ULN at Screening.\n\n              11. Bilirubin level > 2 mg/dL (unless subject has known Gilbert's disease) at\n                  Screening.\n\n              12. Untreated chronic infection or treatment of any infection with systemic\n                  antibiotics, including the ulcer site, within 4 weeks prior to dosing with\n                  investigational product [IP].\n\n              13. Known osteomyelitis.\n\n              14. History of Methicillin-resistant Staphylococcus aureus (MRSA).\n\n              15. Ulcer that has decreased or increased in size by \u2265 50% during the screening\n                  period.\n\n              16. Uncontrolled hypertension (defined as diastolic blood pressure > 100 mmHg or\n                  systolic blood pressure > 180 mmHg during Screening at 2 independent\n                  measurements taken while subject is sitting and resting for at least 5 minutes).\n\n              17. Poorly controlled diabetes mellitus (hemoglobin A1c > 9%).\n\n              18. Untreated proliferative retinopathy.\n\n              19. History of malignant ventricular arrhythmia, CCS Class III-IV angina pectoris,\n                  myocardial infarction/PCI (percutaneous coronary intervention)/CABG (coronary\n                  artery bypass graft) in the preceding 6 months, pending coronary\n                  revascularization in the following 2 months, transient ischemic\n                  attack/cerebrovascular accident in the preceding 6 months, and/or New York Heart\n                  Association [NYHA] Stage III or IV congestive heart failure, (Appendix C).\n\n              20. Abnormal ECG:  new bundle branch block (BBB) \u2265 120 msec in the preceding 3\n                  months; QTcB and/or QTcF > 480 msec or QTcB and/or QTcF \u2265 500 msec with old BBB.\n                  Patients with a potential risk for Torsades des Pointes should not be enrolled.\n\n              21. Uncontrolled hypercoagulation.\n\n              22. Life expectancy less than 2 years due to concomitant illnesses.\n\n              23. In the opinion of the Investigator, the subject is unsuitable for cellular\n                  therapy.\n\n              24. History of malignancy within 5 years except basal cell or squamous cell\n                  carcinoma of the skin or remote history of cancer now considered cured or\n                  positive Pap smear with subsequent negative follow-up.\n\n              25. History of hypersensitivity to any of the components of the product formulation\n                  (including bovine or porcine products, dextran 40, and dimethyl sulfoxide\n                  [DMSO]).\n\n              26. Disorders or allergies precluding the use of radiographic contrast or renal\n                  insufficiency severe enough to contraindicate the use of radiographic contrast.\n\n              27. Subject has received an investigational agent \u2014an agent or device not approved\n                  by the US Food and Drug Administration (FDA) for marketed use in any indication\u2014\n                  within 90 days (or 5 half-lives, whichever is longer) prior to treatment with\n                  study therapy or planned participation in another therapeutic study prior to the\n                  completion of this study.\n\n              28. Subject has received previous gene or cell therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859117", 
            "org_study_id": "CCT-PDA-002-DFU-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "3 x 10^6 cells", 
                "description": "3 x 10^6 cells administered on Study Days 1 and 8", 
                "intervention_name": "3 x 10^6 cells", 
                "intervention_type": "Biological", 
                "other_name": "PDA-002"
            }, 
            {
                "arm_group_label": "10 x 10^6 cells", 
                "description": "10 x 10^6 cells administered on Study Days 1 and 8", 
                "intervention_name": "10 x 10^6 cells", 
                "intervention_type": "Biological", 
                "other_name": "PDA-002"
            }, 
            {
                "arm_group_label": "30 x 10^6 cells", 
                "description": "30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8", 
                "intervention_name": "30 x 10^6 cells", 
                "intervention_type": "Biological", 
                "other_name": "PDA-002"
            }, 
            {
                "arm_group_label": "100 x 10^6 cells", 
                "description": "100 x 10^6 cells administered on Study Days 1 and 8", 
                "intervention_name": "100 x 10^6 cells", 
                "intervention_type": "Biological", 
                "other_name": "PDA-002"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Peripheral arterial disease", 
            "diabetic foot"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85012"
                    }, 
                    "name": "Carl T. Hayden Veterans Affairs Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "University of Arizona"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Veterans Affairs Palo Alto Health Care System"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60064"
                    }, 
                    "name": "Dr. Wiliam M. Scholl College of Podiatric Medicine"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60064"
                    }, 
                    "name": "Rosalind Franklin University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62702"
                    }, 
                    "name": "Southern Illinois University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55407"
                    }, 
                    "name": "Minneapolis Heart Institute Foundation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina School of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "University of Oklahoma Health Sciences Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health and Sciences University (OHSU)"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Endeavor Clinical Trials, PA"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "University of Virginia"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Multicenter, Open-Label, Dose-escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer", 
        "overall_contact": {
            "email": "vhernandez@celgene.com", 
            "last_name": "Vilma Hernandez, Sr. Study Manager", 
            "phone": "732-652-6147"
        }, 
        "overall_official": {
            "affiliation": "Celgene Cellular Therapeutics", 
            "last_name": "Steven A Fischkoff, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the maximum tolerated dose (MTD) of PDA-002 administered intramuscularly (IM) in subjects with peripheral arterial disease (PAD) and DFU [diabetic foot ulcer].", 
                "measure": "Maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "14 days of initial dosing"
            }, 
            {
                "description": "Number of participants with adverse events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From signing informed consent until month 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859117"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "at the ankle by the systolic blood pressures (Doppler technique) in the arm.", 
                "measure": "Ankle-brachial index (ABI)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "description": "To assess changes in the TBI which is calculated by dividing the systolic blood pressure at the toe by the systolic blood pressures (Doppler technique) in the arm.", 
                "measure": "Toe-brachial index (TBI)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}